IMI Members

EU Logo efpia logo

Acting Executive Director

The IMI Governing Board appointed Irene Norstedt as Acting Executive Director of IMI as of 16 December 2014.

Irene Norstedt comes from the European Commission, where she was Head of the Innovative and Personalised Medicine Unit at the European Commission’s Directorate-General for Research and Innovation. She has been at the European Commission since 1996, and was instrumental in the creation of IMI back in 2008. Prior to joining the European Commission, she worked at Swedish life science company Biacore AB and at the Swedish embassy in London.

Irene Norstedt takes over from Michel Goldman, whose mandate as IMI Executive Director ended in December 2014. She will remain in the post until the new Executive Director takes up his duties.


Introducing IMI's new Executive Director, Pierre Meulien

On 15 June 201Pierre Meulien5, IMI announced the appointment of Pierre Meulien as IMI's new Executive Director. His contract will be signed once certain administrative procedures have been completed and he will take up his duties in September 2015.

Pierre Meulien graduated with a degree in microbiology from the University of Liverpool, UK, before moving to the University of Edinburgh where he obtained his PhD in molecular biology in 1981. He then worked as a post-doctoral researcher at the Institut Pasteur in Paris and as a researcher at French biotechnology company Transgene.

In 1991, he took up the post of Director of Research at Aventis Pasteur (now Sanofi Aventis) in France, before moving to Canada in 1998, where he worked as Senior Vice-President R&D for Aventis Pasteur Canada.

From 2002 to 2007, Dr Meulien served as founding CEO of the Dublin Molecular Medicine Centre (now Molecular Medicine Ireland), which linked the three medical schools and six teaching hospitals in Dublin to build a critical mass in molecular medicine and translational research. The Centre managed the €45 million Programme for Human Genomics financed by the Irish government and was responsible for coordinating the successful application for the first Wellcome Trust funded Clinical Research Centre to be set up in Ireland.

In 2007, Dr Meulien moved back to Canada, where he worked until 2010 as Chief Scientific Officer for Genome British Columbia. There, he promoted the organisation's ongoing scientific strategy, focusing on the science of genomics, proteomics and bioinformatics within the larger realm of biotechnology and life sciences. Facilitating the translation of genome based technologies into end user communities across many life science sectors was also a key responsibility.

Since 2010, Dr Meulien has been President and CEO of Genome Canada. While there, he raised CAD$300 million from the Government of Canada which will be leveraged to $CAD900 million through partnerships. For example, a major partnership with the Canadian Institutes of Health Research resulted in the CAD$150 million ‘Genomics and Personalised Health’ programme, which was launched in 2012 and provided funding for 17 projects involving 19 industry partners, academics, clinicians, health economists and health authorities in Canada. He also developed the Genomics Innovation Network (launched in 2015) to keep Canada at the cutting edge of genomics-based technologies and involving 10 highly specialised technology platforms across Canada.

Pierre has Irish nationality.

His declaration of interests will be published here when he formally takes up his duties.

Past IMI Executive Director

Professor Michel Goldman held the post of IMI Executive Director from September 2009 to December 2014. After leaving IMI, he returned to the Université Libre de Bruxelles where he is a Full Professor.